VIDEO: Latest treatment advancements in hyperphosphatemia

Editor’s note: This is an automatically generated transcript. Please notify iwaters@healio.com if there are concerns regarding accuracy of the transcription.

The first treatment advancement that’s now on the market is Ardelyx’s drug, which is a sodium hydrogen exchange inhibitor, and that’s called tenapanor. Brand name, I think, is Xphozah.

This is a different class of drugs than we’ve used before for phosphate control in the dialysis population. It’s exciting to the extent that it is a new mechanism of action, and it can be combined with our present therapies, which are largely phosphate binders. I think other things [that] are not quite to the market yet are a more potent phosphate binder, and maybe we’ll talk about this a little bit more. It may get to the market in the next year or 2. There is another oral drug that inhibits phosphorous through a different mechanism than Ardelyx’s tenapanor.